Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afalaza in BPH with Risk of Progression
NCT01716104Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Nov 2012
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of Afalaza in benign prostatic hyperplasia (BPH), sponsored by Materia Medica Holding. Started Nov 2012; status: completed.
02
Drugs
Afalaza
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01716104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716104.